Who makes Mannitol challenge test & reversibility test?

Mannitol challenge test & reversibility test is developed by Mundipharma AB.

What development phase is Mannitol challenge test & reversibility test in?

Mannitol challenge test & reversibility test is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Mannitol challenge test & reversibility test

Mundipharma AB · FDA-approved active Small molecule Quality 0/100

Mannitol challenge test & reversibility test, marketed by Mundipharma AB, holds a position in the respiratory diagnostics market with a key composition patent expiring in 2028. The primary strength of this diagnostic tool lies in its established market presence and regulatory approval. The main risk is the potential increase in competition following the 2028 patent expiry.

At a glance

Generic name	Mannitol challenge test & reversibility test
Sponsor	Mundipharma AB
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Mannitol Challenge Test in Adult Asthma Patients With Fixed Dose Combinations (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results